Latest Shareholder Approval News

Vectus Biosystems has secured $791,000 through a placement to accelerate its lead fibrosis drug VB0004's Phase IB clinical trial and advance other drug candidates.

SDI Limited has dispatched its Scheme Booklet to shareholders as it moves closer to a $1.40 per share acquisition by a Beijing Guoci subsidiary. The virtual shareholder meeting is set for 22 June 2026 with strong backing from the board and largest shareholder.

Godolphin Resources is spinning out its Narraburra Rare Earths Project into a new ASX-listed entity, Matrix Critical Minerals, with MST Financial appointed to spearhead the IPO expected in the second half of 2026.

Arafura Rare Earths launches a two-tranche A$350 million placement and a A$25 million share purchase plan, closing the equity funding gap for its Nolans Rare Earths Project ahead of construction.

Lefroy Exploration secures $3.6 million through a share placement to fast-track scoping studies and drilling at its Mt Martin and Burns gold deposits, while awaiting cash flow from Lucky Strike.

Many Peaks Minerals has raised A$27.5 million through a placement to fund extensive drilling and a pre-feasibility study at its Ferké Gold Project and other Côte d’Ivoire assets.

PainChek has secured A$5.5 million via convertible notes to accelerate its US sales expansion and strengthen working capital amid key commercial milestones.

White Energy has inked a non-binding term sheet to acquire coal assets in Alabama and Queensland, backed by a $15 million capital raise and planned board reshuffle.

Australian Oil Company Limited is raising $250,000 through a Share Purchase Plan priced at $0.0029 per share, including free-attaching options exercisable by mid-2028. The capital will support oil production enhancements and exploration in Queensland's Surat Basin.

ChemX Materials remains suspended from ASX trading since December 2024, with no exploration activity reported in Q1 2026. The company secured an unsecured $1.2 million loan facility to support its recapitalisation and operational needs.

Little Green Pharma (ASX:LGP) posted a 15.3% revenue increase to AUD 42.5 million in FY2026, driven by European market expansion, yet recorded a $1.4 million loss after tax impacted by significant inventory write-downs.

Comet Ridge has revised its acquisition deal for Santos’ stake in the Mahalo Gas Project, cutting upfront cash and extending deadlines to navigate new government gas reservation policy uncertainty.